Study guide

16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care

WHNP-BC Women's Health Nurse Practitioner Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction: About the WHNP-BC Exam

WHNP-BC Exam Facts, Blueprint & Study Plan

2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening

1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening

3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention

2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites

4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers

3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers

5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility

4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies

6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy

5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion

7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health

6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis

8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care

7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction

9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care

8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy

10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth

9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency

11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions

10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn

12 Chapter 11: Intrapartum Principles & Fetal Surveillance

11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies

13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications

12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs

14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions

13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold

15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders

14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders

16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health

15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis

17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care

16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care

18 Chapter 17: Assessment, Diagnostic Testing & Interpretation

17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities

19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing

18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation

20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities

19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care

16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care

Key Takeaways Explain This Topic AI

Intimate partner violence (IPV) affects approximately 1 in 4 women in the United States, driving long-term somatic sequelae including chronic pelvic pain, STIs, unintended pregnancy, and PTSD; universal screening of all women must be conducted alone in a private, confidential setting.

Non-fatal strangulation is the single strongest clinical predictor of intimate partner femicide, carrying about 7.5 times the odds of later homicide; other critical lethality markers on the Danger Assessment include abuser firearm access, threats to kill, and separation attempts.

In most U.S. jurisdictions, mandatory reporting laws do NOT require clinicians to report IPV disclosures by competent adult patients to law enforcement without patient consent; reporting without consent breaches autonomy and often escalates lethal retaliation.

Acute sexual assault management requires rapid medical, psychological, and forensic intervention within 72 to 120 hours; the empiric prophylactic regimen includes emergency contraception, empiric antimicrobial coverage for gonorrhea, chlamydia, and trichomoniasis, hepatitis B immunization, and a 28-day HIV nPEP regimen initiated within 72 hours.

Trauma-informed care shifts clinical perspective from 'What is wrong with you?' to 'What happened to you?'; trauma-informed pelvic examinations emphasize patient control, explicit verbal consent before every maneuver, table elevation to maintain eye contact, and continuous procedural transparency.

Last updated: October 2026

Epidemiology & Systemic Health Sequelae of Intimate Partner Violence

Intimate Partner Violence (IPV)—encompassing physical violence, contact sexual assault, stalking, psychological aggression, and reproductive coercion by a current or former partner—is a pervasive public health crisis. In the United States, approximately 1 in 4 women (25%) has experienced severe physical violence by an intimate partner in her lifetime, and more than 50% of all female homicides are committed by intimate partners.

Chronic IPV induces sustained allostatic load and immune-neuroendocrine dysregulation, manifesting across organ systems:

Gynecologic & Reproductive Sequelae: Chronic pelvic pain, deep dyspareunia, vulvodynia, recurrent vaginitis, sexually transmitted infections (STIs) including HIV, unintended pregnancies, and rapid-repeat unintended pregnancies.

Reproductive Coercion: Explicit partner behaviors that control a woman's reproductive autonomy, such as birth control sabotage (discarding oral contraceptives, puncturing condoms, removing vaginal rings/IUDs), forced unprotected intercourse, and coercing pregnancy or abortion.

Gastrointestinal & Central Pain Syndromes: Irritable bowel syndrome (IBS), functional dyspepsia, fibromyalgia, tension headaches, and temporomandibular joint dysfunction.

Psychosocial Comorbidities: Major depression, generalized anxiety, panic disorder, post-traumatic stress disorder (PTSD), severe insomnia, and substance use disorders.

Universal Screening Protocols & Safe Administration

The USPSTF (Grade B, for women of reproductive age), ACOG, and other professional groups recommend routine IPV screening for women at well-woman visits, new patient encounters, and at the initial prenatal visit, at least once per trimester, and at the postpartum visit (IPV frequently escalates during pregnancy).

The Mandatory Private Administration Protocol

Universal screening must follow strict protocols to prevent endangering the patient:

Screen in Complete Privacy: The patient must be ALONE . Never screen for IPV in the presence of a partner, family member, friend, or children older than 2 years. Clinics should establish standardized separation policies (e.g., obtaining vital signs or urine samples alone in the examination room).

Professional Medical Interpreters Only: Never use a partner or family member as an interpreter. In-person or remote certified medical interpreters bound by medical confidentiality must be used.

Universal Normalizing Framing: Ask routinely to reduce shame: "Because relationships affect health and violence is so common, I ask all my patients these questions."

Validated Screening Tools

HITS (Hurt, Insult, Threaten, Scream): 4 items scored 1–5; a score >10 indicates a positive screen.

WAST (Woman Abuse Screening Tool): Assesses relationship tension and argument difficulty.

Direct Clinical Inquiry: "Within the past year, has a partner hit, slapped, kicked, choked, or hurt you? Do you feel safe in your relationship?"

Behavioral Red Flags & Physical Indicators

Partner Behaviors: Insists on remaining in the room, answers questions on the patient's behalf, hovers closely, displays hostility or excessive attentiveness, and attempts to control clinical management.

Patient Behaviors: Avoidant eye contact, flattened affect, hypervigilance, defensive posturing, missing appointments, late entry to prenatal care, or sudden treatment non-adherence.

Physical Exam Findings: Injuries inconsistent with reported mechanisms; variegated ecchymoses in multiple stages of healing; defensive injuries along the ulnar forearms or palms; bilateral tympanic membrane ruptures; and contusions concentrated on central body areas ( head, face, neck, breasts, abdomen, genitalia ).

Lethality Assessment: The Danger Assessment & Strangulation

When IPV is disclosed, clinicians must evaluate lethality risk using evidence-based tools, such as the Danger Assessment :

Important

Non-Fatal Strangulation as a 7.5-Fold Femicide Predictor: Non-fatal strangulation (often called "choking" by patients) is the single strongest clinical predictor of subsequent intimate partner femicide . A woman who has suffered non-fatal strangulation has about 7.5 times the odds of being killed by that partner in the future.

In addition to lethality, strangulation causes severe occult trauma: internal jugular vein and carotid artery compression, tracheal and hyoid fractures, anoxic brain injury, and carotid artery dissection leading to delayed stroke days or weeks later. Clinical signs include:

  • Petechiae on the face, eyelids, conjunctiva, and soft palate
  • Neck tenderness, ligature marks, or scratch marks
  • Dysphonia (hoarseness), odynophagia, dyspnea, or stridor

Any patient with a history of strangulation and persistent neck pain, hoarseness, or neurological symptoms requires emergency transfer for CT angiography (CTA) of the neck.

Key Red-Flag Lethality Markers

Abuser has access to, owns, or has threatened the victim with firearms (increases homicide risk 5-fold).

Abuser has made explicit threats to kill the patient, her children, or himself.

Acute separation or attempting to leave: The period surrounding separation is the single most lethal window for intimate partner femicide.

Abuser forced sexual intercourse, is unemployed, or exhibits obsessive stalking and daily monitoring.

Patient-Centered Safety Planning & Legal Frameworks

Clinicians must validate disclosures ( "You do not deserve to be hurt; I am concerned for your safety; help is available" ) without forcing immediate departure, recognizing that abrupt separation can trigger lethal violence.

Safety Plan Components

Escape Route & Safe Destination: Identify safe exits and a secure destination (shelter, trusted friend).

Distress Code Word: Establish a code word with trusted contacts or children signaling an immediate 911 call.

Emergency Go-Bag: Store vital documents (birth certificates, passports, social security cards, driver's license, cash, medications, keys) with a trusted contact outside the home.

Digital Safety: Check smartphones for spyware or tracking devices; browse in private windows on public devices.

Crisis Resources: Direct connection to the National Domestic Violence Hotline (1-800-799-SAFE [7233], text "START" to 88788).

Mandatory Reporting Distinctions in Competent Adults

Competent Adults: In the vast majority of U.S. states, IPV disclosures by competent adult patients are NOT mandatorily reportable to police without patient consent . Reporting against a patient's will violates autonomy, destroys clinical trust, and can provoke retaliatory homicide.

Statutory Exceptions: Specific state laws mandate reporting injuries resulting from firearms (gunshots), knives/sharp weapons (stabbings), or severe burns/felony trauma .

Mandatory Reporting Populations: Every state requires clinicians to report suspected child abuse or neglect . Most states also require reporting of suspected abuse, neglect, or exploitation of older adults and vulnerable adults with disabilities , but the age threshold, who must report, and the receiving agency vary by state, so know your state's adult protective services law.

Acute Sexual Assault Care & Post-Assault Prophylaxis

Care is optimally delivered by a Sexual Assault Nurse Examiner (SANE) . Forensic evidence collection (SAECK) should occur within 72 to 120 hours (up to 5 days) , preserving strict chain of custody. The patient maintains autonomy to accept medical care while declining forensic collection or police involvement.

Prophylaxis Category Clinical Regimen (CDC 2021 Guidelines) Timing & Notes

Emergency Contraception (EC) • Copper IUD: Most effective option; inserted within 120 hours. • Ulipristal Acetate (Ella): 30 mg PO single dose within 120 hours. • Levonorgestrel (Plan B): 1.5 mg PO single dose within 72–120 hours. Baseline urine pregnancy test required. Ulipristal preferred over levonorgestrel if BMI >25 kg/m² or presenting 72–120 hours post-assault.

Empiric STI Coverage (Gonorrhea, Chlamydia, Trichomoniasis) • Ceftriaxone: 500 mg IM single dose (1,000 mg if weight ≥150 kg). • Doxycycline: 100 mg PO BID for 7 days. • Metronidazole: 500 mg PO BID for 7 days. Doxycycline replaces historical azithromycin due to superior efficacy. (Use azithromycin 1 g PO single dose if pregnant). Metronidazole BID replaces historical 2 g single dose.

Hepatitis B Virus (HBV) • HBV Vaccine: 1st dose today (follow-up at 1–2 and 4–6 months). • HBIG: Add Hepatitis B Immune Globulin (0.06 mL/kg IM) if assailant is known HBsAg-positive and patient is unvaccinated. Administer vaccine to all unvaccinated patients. HBIG must be given within 14 days of sexual exposure.

HIV Non-Occupational Post-Exposure Prophylaxis (nPEP) 28-day regimen (CDC 2025 update): preferred single tablet bictegravir/emtricitabine/tenofovir alafenamide once daily, or dolutegravir plus tenofovir (TAF or TDF) with emtricitabine. Start as soon as possible, ideally within 24 hours and no later than 72 hours . Baseline HIV Ag/Ab, creatinine, and hepatitis serologies; follow up at 24 hours and test at 4–6 and 12 weeks.

Tetanus Prophylaxis Tdap / Td booster (0.5 mL IM). Administer if physical trauma exists and >5 years since last booster.

Principles of Trauma-Informed Care & Pelvic Examinations

Trauma-Informed Care (TIC) shifts perspective from "What is wrong with you?" to "What happened to you?" SAMHSA establishes Six Core Principles : Safety, Trustworthiness & Transparency, Peer Support, Collaboration & Mutuality, Empowerment/Voice/Choice, and Cultural/Historical/Gender Humility.

Trauma-Informed Pelvic Examination Techniques

Explicit Step-by-Step Consent: Seek permission before each maneuver: "You are in complete control of this exam. If you want me to pause or stop, let me know, and I will stop immediately."

Table Elevation: Elevate the examination table backrest to 30 to 45 degrees rather than leaving the patient supine. This maintains eye contact, situational control, and prevents feelings of helpless subjugation.

Preparation & Touch: Never touch without verbal warning. Warm the speculum with warm water or lubricant. Touch the inner thigh with the back of a gloved hand first to provide sensory grounding before approaching the genitalia.

Empowering Language: Avoid commands like "Just relax" or "Open your legs." Use collaborative phrasing: "When you are ready, let your knees fall gently outward."

Grounding: If panic or dissociation occurs, stop immediately. Re-anchor the patient in the present using sensory grounding (holding cold water, naming objects in the room, deep breathing).

Family Violence, Child Maltreatment & Elder Mistreatment

IPV rarely occurs alone. Children in homes with IPV are more likely to be abused themselves and to witness violence, which is an adverse childhood experience (ACE) linked to later depression, substance use, and chronic disease.

Child Maltreatment

Forms: Physical abuse, sexual abuse, emotional abuse, and neglect (the most common form).

Red flags: Injuries that do not match the history or the child's developmental stage, delays in seeking care, patterned bruises or burns, bruising in an infant who is not yet cruising, and sexually transmitted infections in a prepubertal child.

The WHNP's role: Ask a parent experiencing IPV about the children's safety, report reasonable suspicion to child protective services (proof is not required), and connect the family with home-visiting and parenting support. Reporting in good faith is legally protected.

Elder Mistreatment

Forms: Physical, sexual, and psychological abuse; neglect (including self-neglect); and financial exploitation , one of the most common forms in older women.

Red flags: Unexplained bruises or fractures, poor hygiene or weight loss, missed appointments, a caregiver who answers for the patient or refuses to leave the room, sudden changes in finances or legal documents, and untreated pressure injuries.

Assessment: Interview the patient alone and assess cognition and decision-making capacity. Brief tools such as the Elder Abuse Suspicion Index (EASI) help structure questions. USPSTF finds the evidence insufficient to recommend for or against routine screening of older or vulnerable adults for abuse and neglect, so the WHNP stays alert to signs and asks when they appear.

Response: Treat injuries, address safety, involve social work, and report to adult protective services as state law requires. A competent older adult may decline services, just as a competent younger adult experiencing IPV may.